Phase 2 ALPACA Study Shows siRNA therapy demonstrated sustained 93.9% Lp(a) Reduction
Time to read: 01:21. Eli Lilly’s Phase 2 ALPACA study demonstrated that lepodisiran, an investigational siRNA therapy, significantly reduced lipoprotein(a) [Lp(a)] levels—a key genetic risk factor for cardiovascular disease.
Source: PressRelease, Lilly
Feature
Text
Muvalaplin, a first-of-its-kind oral medication demonstrates significant potential in lowering lipoprotein(a) (Lp(a)) levels: KRAKEN Trial
Time to read: 01:52.Muvalaplin, a first-of-its-kind oral medication, has demonstrated significant potential in lowering lipoprotein(a) (Lp(a)) levels—a critical yet untreatable cardiovascular risk factor—according to findings from the phase 2 KRAKEN trial.
Source: AHA, JAMA
Text
Promising solutions for Aortic disease – Artivion presents data from three new trials at EACTS
Time to read: 02:24. Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its AMDS DARTS and PERSEVERE trials and E-vita Open Neo study presented in Late-Breaking Science presentations at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Lisbon, Portugal
Source: PR Newswire
Text
Boston Scientific Receives FDA Approval for Expanded Indication of INGEVITY™ Leads
Boston Scientific has received FDA approval to expand the use of its INGEVITY™+ Pacing Leads to include conduction system pacing (CSP) and left bundle branch area (LBBA) sensing when connected to single- or dual-chamber pacemakers.
Source: PR NewsWire, Boston Scientific
Text
